Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics
Wong, S.-Y.; Gold, S.; Accorsi, E. K.; Cowger, T. L.; Wiseman, D.; Navalurkar, R.; Dixon, R.; Helmus, D. S.; CiTI Study Group, ; Firpo-Betancourt, A.; Mendu, D. R.; Zolla-Pazner, S.; Cadwell, K.; Colombel, J.-F.
Show abstract
Patients with immune-mediated inflammatory diseases (IMIDs) and acquired and genetic immunodeficiencies receiving therapeutic infusions are considered high risk for SARS-CoV-2 infection. However, the seroprevalance in this group and the safety of routine administrations at outpatient infusion centers are unknown. To determine the infection rate and clinical-social factors related to SARS-CoV-2 in asymptomatic patients with IMIDs and immunodeficiencies receiving routine non-cancer therapeutic infusions, we conducted a seroprevalence study at our outpatient infusion center. We report the first prospective SARS-CoV-2 sero-surveillance of 444 IBD/IMID, immunodeficiency, and immune competent patients at an outpatient infusion center in the U.S. showing lower seroprevalence in patients compared with the general population and provide clinical and social characteristics associated with seroprevalence in this group. These data suggest that patients can safely continue infusions at outpatient centers.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.